Peripheral Exudative Hemorrhagic Chorioretinopathy: A Clinical, Angiographic, and Histologic Study

In light of her monocular status with only the right eye providing functional vision, intravitreal bevacizumab (2.5 mg in 0.1 mL; Genentech/Roche, San Francisco, California, USA) was offered off-label to the patient to prevent extension of hemorrhage into the macula. In the other patient (83 years o...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of ophthalmology Vol. 149; no. 6; p. 1013
Main Authors Gonzales, John A, Kapoor, Kapil G, Gibran, Syed K
Format Journal Article
LanguageEnglish
Published Chicago Elsevier Limited 01.06.2010
Subjects
Eyes & eyesight
Hemorrhage
Medical imaging
Retina
Online AccessGet full text

Cover

More Information
Summary:In light of her monocular status with only the right eye providing functional vision, intravitreal bevacizumab (2.5 mg in 0.1 mL; Genentech/Roche, San Francisco, California, USA) was offered off-label to the patient to prevent extension of hemorrhage into the macula. In the other patient (83 years old), a large macula-off inferotemporal hemorrhagic retinal detachment warranted drainage of the subretinal hemorrhage in a manner previously described.2 In addition, intravitreal bevacizumab (2.5 mg in 0.1 mL) was administered to prevent new subretinal hemorrhages.
ISSN:0002-9394
1879-1891
DOI:10.1016/j.ajo.2010.02.018;10.1016/j.ajo.2009.06.032